Sign in

    Destiny Buch

    Research Analyst at Ladenburg Thalmann & Co. Inc.

    Destiny Alexandra Hance Buch is Vice President of Equity Research at Ladenburg Thalmann & Co. Inc., specializing in equity research with coverage including companies such as Jaguar Health, Inc. and Artivion Inc. She has played a key role in leading research showcases and earnings calls for these firms, contributing to actionable insights for institutional investors. Destiny started her finance career as an equity research intern at Ladenburg Thalmann in 2017, advancing through associate and senior associate roles before becoming Vice President in 2021, following early experience in data, marketing, and analysis roles. She holds a Bachelor of Science in Entrepreneurship from Lynn University, an MBA from the University of Florida, and professional credentials including a FINRA Series 7 license and certifications in financial analysis from S&P Global Market Intelligence.

    Destiny Buch's questions to Nano-X Imaging (NNOX) leadership

    Destiny Buch's questions to Nano-X Imaging (NNOX) leadership • Q4 2024

    Question

    Destiny Buch inquired about the sales model for the Nanox.ARC system with Durable Medical Equipment (DME) partners in the U.S., asking whether sales would be outright capital expenditures or based on an imaging-as-a-service model.

    Answer

    Erez Meltzer, Chief Executive Officer, clarified that Nano-X will utilize both sales models with its DME partners. Some partners will facilitate direct CapEx sales, handling the installation and sales process, while others will operate under the company's typical MSaaS (Medical-System-as-a-Service) model.

    Ask Fintool Equity Research AI

    Destiny Buch's questions to Bionano Genomics (BNGO) leadership

    Destiny Buch's questions to Bionano Genomics (BNGO) leadership • Q3 2024

    Question

    Destiny Buch, on for Jeff Cohen, asked about the expected growth rate for consumables in 2025 given the new CPT code, whether recent top-line revenue delays would be recovered in Q4, and if Bionano had plans for new partnership-based clinical studies.

    Answer

    CEO Erik Holmlin did not provide specific guidance but outlined key drivers for consumable growth, including the CPT code, customers transitioning to routine use, and wider adoption of VIA software. He confirmed that revenue delays were timing-related to customer capital purchase approvals and are factored into Q4 guidance. Regarding studies, he noted that leadership of existing trials is being transitioned to principal investigators to save costs and that while the company is open to partnerships, there are no definitive plans for new ones.

    Ask Fintool Equity Research AI

    Destiny Buch's questions to CareCloud (CCLD) leadership

    Destiny Buch's questions to CareCloud (CCLD) leadership • Q3 2024

    Question

    Destiny Buch of B. Riley Securities inquired about the newly mentioned life science partnerships, asking for more detail on the types of companies involved and the scope of these collaborations, including potential involvement in clinical trial support.

    Answer

    A. Chaudhry, an executive, explained that these partnerships leverage CareCloud's extensive 20-year clinical and financial data asset. He cited a recent partnership for medicine adherence as an example and confirmed the company is exploring all opportunities to monetize its data, including supporting life sciences companies with research and risk assessment. While revenue from this area is currently modest, it is expected to be a more significant contributor in the coming year.

    Ask Fintool Equity Research AI

    Destiny Buch's questions to OPKO HEALTH (OPK) leadership

    Destiny Buch's questions to OPKO HEALTH (OPK) leadership • Q3 2024

    Question

    Destiny Buch, on behalf of Jeff Cohen, asked for clarification on the MDX-2201 EBV vaccine program, specifically regarding who makes the decision to advance it into the clinic. She also questioned whether BioReference's path to profitability requires additional investment or if the current restructuring and cost-cutting measures are sufficient.

    Answer

    Executive Elias Zerhouni clarified that Merck, as the program sponsor, holds the final decision-making authority for advancing MDX-2201 and that there are no outstanding obstacles. Regarding BioReference, executive Adam Logal stated that the nonrecurring restructuring costs are the primary driver for profitability and significant new investments are not required. Zerhouni added that rightsizing the infrastructure and focusing on the NY/NJ market will drive efficiency.

    Ask Fintool Equity Research AI

    Destiny Buch's questions to NovaBay Pharmaceuticals (NBY) leadership

    Destiny Buch's questions to NovaBay Pharmaceuticals (NBY) leadership • Q2 2024

    Question

    Destiny Buch inquired about the outlook for wound care product orders, the drivers of marketing efficiencies, the revenue contribution from the 'Subscribe & Save' program, and the expected quarterly revenue cadence for the remainder of the year. She also asked about the strategic role of the physician-dispensed channel, supply chain dynamics affecting gross margins, and the status of partnerships, including international expansion plans.

    Answer

    Executive Justin Hall explained that future wound care orders will be smaller than in 2023. He detailed a strategic shift in marketing towards retaining 'Subscribe & Save' customers, who now account for about 24% of online revenue, making spending more efficient. Hall anticipates a stronger Q4 than Q3, driven by physician channel and back-to-school pushes. He emphasized the physician channel's importance for acquiring high-value online customers. He and CFO Tommy Law clarified that margin improvement was due to product mix, with stable eyecare margins around 65%, not supply chain changes. Hall concluded that partnerships are the main focus, with no plans for direct international expansion.

    Ask Fintool Equity Research AI